Serum antibody immunoreactivity and safety of native porcine and recombinant zona pellucida vaccines formulated with a non-Freund’s adjuvant in horses

dc.contributor.authorNolan, Margaret Bethaline
dc.contributor.authorSchulman, M.L. (Martin)
dc.contributor.authorBotha, A.E. (Alma)
dc.contributor.authorHuman, Anne-Marie
dc.contributor.authorRoth, Robyn
dc.contributor.authorCrampton, Michael C.
dc.contributor.authorBertschinger, Hendrik Jan
dc.contributor.emailmargaret.nolan@up.ac.zaen_ZA
dc.date.accessioned2019-07-26T10:32:19Z
dc.date.issued2019-02
dc.description.abstractCommercial and regulatory limitations associated with native porcine zona pellucida (pZP) vaccines formulated with Freund’s adjuvants may be overcome by developing effective recombinant ZP vaccines (reZP) and identifying alternative adjuvant formulations. A two-part preparatory study used 15 geldings and identified potentially effective alternative adjuvant formulations based on anti-pZP antibody response following treatment with pZP formulated with Addavax (AddaVax ™, Invivogen), Quil A (Quil-A® Adjuvant, Invivogen), Quil A and Poly (I:C) (HMW VacciGrade™, Invivogen), Pet Gel A (Montanide™ Pet Gel A, Seppic) and Pet Gel A and Poly (I:C). Injection site reactions, rectal temperature and respiratory and heart rates were also monitored for three days post-treatment. Suitable anti-pZP antibody titres were seen in response to Pet Gel A and Pet Gel A and Poly (I:C). Subsequently in 31 mares, following administration of pZP, reZP and a combination of pZP and reZP proteins prepared in Pet Gel A and Poly (I:C), both serum anti-pZP and -reZP antibody responses were monitored. In addition, safety was assessed for up to seven days post-treatment by inspection and palpation of gluteal intramuscular injection sites and measurement of rectal temperature. The measured antibody titres in all treatment groups differed significantly to an adjuvant control group (P < 0.001). Temporal changes in both anti-pZP and -reZP antibody titres in all ZP treatment groups were similar to patterns reported previously in various species vaccinated with pZP formulated with Freund’s adjuvants. There were no differences in anti-pZP antibody titres between the pZP and reZP treated groups (P > 0.05). Side effects were mild and transient in nature. This represents the first application of a reZP vaccine formulated with non-Freund’s adjuvants evoking a similar antibody titre response to native pZP vaccination in mares.en_ZA
dc.description.departmentProduction Animal Studiesen_ZA
dc.description.embargo2020-02-28
dc.description.librarianhj2019en_ZA
dc.description.sponsorshipThe Technology Innovation Agency, Pretoria, South Africa.en_ZA
dc.description.urihttp://www.elsevier.com/locate/vaccineen_ZA
dc.identifier.citationNolan, M.B., Schulman, M.L., Botha, A.E. et al. 2019, 'Serum antibody immunoreactivity and safety of native porcine and recombinant zona pellucida vaccines formulated with a non-Freund’s adjuvant in horses', Vaccine, vol. 37, no. 10, pp. 1299-1306.en_ZA
dc.identifier.issn0264-410X (print)
dc.identifier.issn1873-2518 (online)
dc.identifier.other10.1016/j.vaccine.2019.01.053
dc.identifier.urihttp://hdl.handle.net/2263/70800
dc.language.isoenen_ZA
dc.publisherElsevieren_ZA
dc.rights© 2019 Elsevier Ltd. All rights reserved. Notice : this is the author’s version of a work that was accepted for publication in Vaccine. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. A definitive version was subsequently published in Vaccine, vol. 37, no. 10, pp. 1299-1306, 2019. doi : 10.1016/j.vaccine.2019.01.053.en_ZA
dc.subjectPorcine zona pellucida (pZP)en_ZA
dc.subjectRecombinant ZP vaccines (reZP)en_ZA
dc.subjectHorse (Equus caballus)en_ZA
dc.subjectVaccine formulationen_ZA
dc.subjectImmunocontraceptionen_ZA
dc.subjectZona pellucida proteinsen_ZA
dc.subjectAntibody titresen_ZA
dc.titleSerum antibody immunoreactivity and safety of native porcine and recombinant zona pellucida vaccines formulated with a non-Freund’s adjuvant in horsesen_ZA
dc.typePostprint Articleen_ZA

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Nolan_Serum_2019.pdf
Size:
432.63 KB
Format:
Adobe Portable Document Format
Description:
Postprint Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: